We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

AnaptysBio Inc (ANAB) USD0.001

Sell:$30.65 Buy:$30.71 Change: $0.47 (1.51%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Sell:$30.65
Buy:$30.71
Change: $0.47 (1.51%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Sell:$30.65
Buy:$30.71
Change: $0.47 (1.51%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AnaptysBio, Inc. is a clinical stage biotechnology company. The Company is developing immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. It develops its product candidates using its antibody discovery technology platform, which is based upon the natural process of antibody generation, known as somatic hypermutation (SHM), and replicates this natural process of antibody generation in vitro. Its product pipeline includes Imsidolimab, ANB030 (Rosnilimab), ANB032, JEMPERLI, GSK4069889 (cobolimab), GSK4074386 and CC-90006. its Imsidolimab is an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of multiple dermatological inflammatory diseases. ANB030 is an antibody that binds PD-1 in an agonistic manner to suppress T cell activity and anti-inflammatory effects in vivo.

Contact details

Address:
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO
92121
United States
Telephone:
+1 (858) 3626295
Website:
https://www.anaptysbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ANAB
ISIN:
US0327241065
Market cap:
$856.05 million
Shares in issue:
27.45 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Hamza Suria
    President, Chief Executive Officer, Director
  • Dennis Mulroy
    Chief Financial Officer
  • Eric Loumeau
    Chief Operating Officer, General Counsel
  • Paul Lizzul
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.